Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer

Oncogene

Volumn 34, Issue 38, 2015, Pages 4914-4927

  Lemieux, E ^a   Cagnol, S ^a   Beaudry, K ^a   Carrier, J ^a   Rivard, N ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AXIN; AXIN2; B RAF KINASE; BETA CATENIN; FRIZZLED PROTEIN; K RAS PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LYMPHOID ENHANCER FACTOR 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MYC PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; LRP6 PROTEIN, HUMAN; SERINE; TCF4 PROTEIN, HUMAN; THREONINE; TRANSCRIPTION FACTOR;

ADENOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL TRANSFORMATION; COLORECTAL CANCER; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE EPITHELIUM CELL; METASTASIS POTENTIAL; MOUSE; MUTANT; NONHUMAN; ONCOGENE C MYC; ONCOGENE K RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; CHEMISTRY; COLORECTAL TUMOR; GENETICS; METABOLISM; ONCOGENE; ONCOGENE RAS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; ONCOGENES; PHOSPHORYLATION; SERINE; SIGNAL TRANSDUCTION; THREONINE; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY;

EID: 84941875187     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.416     Document Type: Article

References (86)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759767.
2. Gregorieff A, Clevers H. Wnt signalling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005; 19: 877-890.
3. Taketo MM. Mouse models of gastrointestinal tumors. Cancer Sci 2006; 97: 355-361.
4. Ashton GH, Morton JP, Myant K, Phesse TJ, Ridgway RA, Marsh V, et al. Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signalling. Dev Cell 2010; 19: 259-269.
5. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007; 446: 676-679.
6. Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev 2010; 31: 31-38.
7. Pretlow TP, Pretlow TG. Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? Biochim Biophys Acta 2005; 1756: 83-96.
8. Smakman N, Borel Rinkes IH, Voest EE, Kranenburg O. Control of colorectal metastasis formation by K-Ras. Biochim Biophys Acta 2005; 1756: 103-114.
9. Saucier C, Rivard N. Epithelial cell signalling in colorectal cancer metastasis. In: Beauchemin N, Huot J (eds) Metastasis of Colorectal Cancer vol.14. Springer: Netherlands, 2010, pp 205-241.
10. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res 2010; 16: 3811-3818.
11. Dienstmann R, Tabernero J. BRAF as a target for cancer therapy. Anticancer Agents Med Chem 2011; 11: 285-295.
12. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005; 65: 4562-4567.
13. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 191-195.
14. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006; 5: 2.
15. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62: 6451-6455.
16. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
17. Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 2008; 40: 2707-2719.
18. Aliaga JC, Deschenes C, Beaulieu JF, Calvo EL, Rivard N. Requirement of the MAP kinase cascade for cell cycle progression and differentiation of human intestinal cells. Am J Physiol 1999; 277: G631-G641.
19. Rivard N, Boucher MJ, Asselin C, L'Allemain G. MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells. Am J Physiol 1999; 277: C652-C664.
20. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005; 6: 322-327.
21. Eggstein S, Franke M, Kutschka I, Manthey G, von Specht BU, Ruf G, et al. Expression and activity of mitogen activated protein kinases in human colorectal carcinoma. Gut 1999; 44: 834-838.
22. Lee SH, Lee JW, Soung YH, Kim SY, Nam SW, Park WS, et al. Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. APMIS 2004; 112: 233-238.
23. Boucher MJ, Jean D, Vezina A, Rivard N. Dual role of MEK/ERK signalling in senescence and transformation of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2004; 286: G736-G746.
24. Lemieux E, Bergeron S, Durand V, Asselin C, Saucier C, Rivard N. Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. Int J Cancer 2009; 125: 1575-1586.
25. Komatsu K, Buchanan FG, Katkuri S, Morrow JD, Inoue H, Otaka M, et al. Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Gastroenterology 2005; 129: 577-590.
26. Voisin L, Julien C, Duhamel S, Gopalbhai K, Claveau I, Saba-El-Leil MK, et al. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer 2008; 8: 337-2407-8-337.
27. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5: 810-816.
28. Ikenoue T, Hikiba Y, Kanai F, Aragaki J, Tanaka Y, Imamura J, et al. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res 2004; 64: 3428-3435.
29. Cagnol S, Rivard N. Oncogenic KRAS and BRAF activation of the MEK/ERK signalling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene 2013; 32: 564-576.
30. Nandan MO, McConnell BB, Ghaleb AM, Bialkowska AB, Sheng H, Shao J, et al. Kruppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis. Gastroenterology 2008; 134: 120-130.
31. Brondello JM, Brunet A, Pouyssegur J, McKenzie FR. The dual specificity mitogenactivated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem 1997; 272: 1368-1376.
32. Brunet A, Pages G, Pouyssegur J. Growth factor-stimulated MAP kinase induces rapid retro-phosphorylation and inhibition of MAP kinase kinase (MEK1). FEBS Lett 1994; 346: 299-303.
33. Gopalbhai K, Meloche S. Repression of mitogen-activated protein kinases ERK1/ERK2 activity by a protein tyrosine phosphatase in rat fibroblasts transformed by upstream oncoproteins. J Cell Physiol 1998; 174: 35-47.
34. Tian X, Liu Z, Niu B, Zhang J, Tan TK, Lee SR, et al. E-cadherin/beta-catenin complex and the epithelial barrier. J Biomed Biotechnol 2011; 2011: 567305.
35. Yochum GS, Cleland R, Goodman RH. A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. Mol Cell Biol 2008; 28: 7368-7379.
36. Clevers H. Wnt/beta-catenin signalling in development and disease. Cell 2006; 127: 469-480.
37. Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, Imai K, et al. Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of betacatenin/T-cell factor 4-mediated gene transactivation. Cancer Res 2001; 61: 2751-2758.
38. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-250.
39. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. Proc Natl Acad Sci USA 2004; 101: 12682-12687.
40. Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A, et al. APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci USA 2000; 97: 3352-3357.
41. Yang J, Zhang W, Evans PM, Chen X, He X, Liu C. Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 2006; 281: 17751-17757.
42. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 1999; 9: 207-210.
43. Piedra J, Miravet S, Castano J, Palmer HG, Heisterkamp N, Garcia de Herreros A, et al. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol Cell Biol 2003; 23: 2287-2297.
44. Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W. Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes Dev 2004; 18: 2225-2230.
45. Roura S, Miravet S, Piedra J, Garcia de Herreros A, Dunach M. Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. J Biol Chem 1999; 274: 36734-36740.
46. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2006; 281: 9971-9976.
47. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 2007; 282: 11221-11229.
48. He XC, Yin T, Grindley JC, Tian Q, Sato T, Tao WA, et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 2007; 39: 189-198.
49. Krejci P, Aklian A, Kaucka M, Sevcikova E, Prochazkova J, Masek JK, et al. Receptor tyrosine kinases activate canonical WNT/beta-catenin signalling via MAP kinase/LRP6 pathway and direct beta-catenin phosphorylation. PLoS ONE 2012; 7: e35826.
50. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE J, et al. Braf (V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41: 544-552.
51. Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013; 3: 742-750.
52. Casalino L, De Cesare D, Verde P. Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol Cell Biol 2003; 23: 4401-4415.
53. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci USA 2013; 110: 20224-20229.
54. Proffitt KD, Virshup DM. Precise regulation of porcupine activity is required for physiological Wnt signalling. J Biol Chem 2012; 287: 34167-34178.
55. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2011; 2: 344-358.
56. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-465.
57. Niault TS, Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis 2010; 31: 1165-1174.
58. Daugherty RL, Gottardi CJ. Phospho-regulation of Beta-catenin adhesion and signalling functions. Physiology (Bethesda) 2007; 22: 303-309.
59. Bienz M. beta-Catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol 2005; 15: R64-R67.
60. Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol 2000; 148: 399-404.
61. Harris TJ, Peifer M. Decisions, decisions: beta-catenin chooses between adhesion and transcription. Trends Cell Biol 2005; 15: 234-237.
62. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483-1487.
63. Perez-Moreno M, Fuchs E. Catenins: keeping cells from getting their signals crossed. Dev Cell 2006; 11: 601-612.
64. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 2012; 148: 639-650.
65. Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signalling. Cancer Res 2012; 72: 1547-1556.
66. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, et al. A twostep model for colon adenoma initiation and progression caused by APC loss. Cell 2009; 137: 623-634.
67. Wang C, Zhao R, Huang P, Yang F, Quan Z, Xu N, et al. APC loss-induced intestinal tumorigenesis in Drosophila: roles of Ras in Wnt signalling activation and tumor progression. Dev Biol 2013; 378: 122-140.
68. Bennecke M, Kriegl L, Bajbouj M, Retzlaff K, Robine S, Jung A, et al. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 2010; 18: 135-146.
69. Rad R, Cadinanos J, Rad L, Varela I, Strong A, Kriegl L, et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 2013; 24: 15-29.
70. Carragher LAS, Snell KR, Giblett SM, Aldridge VSS, Patel B, Cook SJ, et al. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med 2010; 2: 458-471.
71. Zeller E, Hammer K, Kirschnick M, Braeuning A. Mechanisms of RAS/beta-catenin interactions. Arch Toxicol 2013; 87: 611-632.
72. Fodde R, Tomlinson I. Nuclear beta-catenin expression and Wnt signalling: in defence of the dogma. J Pathol 2010; 221: 239-241.
73. Tamai K, Zeng X, Liu C, Zhang X, Harada Y, Chang Z, et al. A mechanism for Wnt coreceptor activation. Mol Cell 2004; 13: 149-156.
74. Wolf J, Palmby TR, Gavard J, Williams BO, Gutkind JS. Multiple PPPS/TP motifs act in a combinatorial fashion to transduce Wnt signalling through LRP6. FEBS Lett 2008; 582: 255-261.
75. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signalling. Cell 2008; 133: 340-353.
76. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signalling in intestinal tumor formation and progression. Gastroenterology 2006; 131: 1096-1109.
77. Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE, et al. Mutated K-ras (Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int J Exp Pathol 2009; 90: 558-574.
78. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008; 40: 600-608.
79. Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J, et al. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med 2010; 16: 665-670.
80. Obrador-Hevia A, Chin SF, Gonzalez S, Rees J, Vilardell F, Greenson JK, et al. Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. J Pathol 2010; 221: 57-67.
81. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov 2014; 13: 513-532.
82. Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, et al. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA 2010; 107: 15473-15478.
83. Bergeron S, Lemieux E, Durand V, Cagnol S, Carrier JC, Lussier JG, et al. The serine protease inhibitor serpinE2 is a novel target of ERK signalling involved in human colorectal tumorigenesis. Mol Cancer 2010; 9: 271-4598-9-271.
84. Simoneau M, Coulombe G, Vandal G, Vezina A, Rivard N. SHP-1 inhibits betacatenin function by inducing its degradation and interfering with its association with TATA-binding protein. Cell Signal 2011; 23: 269-279.
85. Langlois MJ, Bergeron S, Bernatchez G, Boudreau F, Saucier C, Perreault N, et al. The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PLoS ONE 2010; 5: e15742.
86. Madison BB, Dunbar L, Qiao XT, Braunstein K, Braunstein E, Gumucio DL. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem 2002; 277: 33275-33283.